Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ocrelizumab on Neuroinflammation in MS Measured by 11C-PBR28 MR-PET
NCT04230174Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ocrelizumab in multiple sclerosis (MS), sponsored by Massachusetts General Hospital. Started Dec 2020; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04230174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230174.